Develop High-Precision and Multiplex Base Editing Approaches for Therapeutic Applications
开发用于治疗应用的高精度和多重碱基编辑方法
基本信息
- 批准号:10591575
- 负责人:
- 金额:$ 52.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-05 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdenineAffectAllelesBicarbonatesBiomedical ResearchCRISPR/Cas technologyCell LineCellsCharacteristicsChloridesChronic lung diseaseComplexComputer AssistedCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorCytosineDNADNA Sequence AlterationDeaminaseDeaminationDependenceDiseaseDisease modelDrug CombinationsEndonuclease IEngineeringEpithelial CellsExocrine pancreatic insufficiencyFunctional disorderGenesGenetic DiseasesGenomeGenomicsGoalsGuide RNAHereditary DiseaseHeterozygoteHuman EngineeringHuman GeneticsHuman GenomeIon ChannelLengthLungModelingMutationNonsense MutationNucleotidesOrgan failureOther GeneticsOutcomePancreasPathogenicityPatientsPerformancePharmaceutical PreparationsPoint MutationProtein EngineeringRare DiseasesRegulator GenesResearchResolutionRiskSafetySiteSomatic CellStreptococcus pyogenesSymptomsSystemTerminator CodonTherapeuticTrans-SplicingTransfer RNATransportationVariantairway epitheliumautosomebasebase editingbase editorcystic fibrosis patientsdesigndrug discoveryefficacy validationflexibilitygene therapygenetic approachimprovedindividual patientinsertion/deletion mutationinteinmutation correctionnext generationnucleobasepharmacologicprecise genome editingprematurepreventrepairedrespiratoryreverse geneticsrisk minimizationsmall moleculesymptomatic improvementtherapeutic genome editingtooltransition mutation
项目摘要
Project Summary/Abstract
Genetic disorders and genetic diseases are caused by insertions, deletions, and base substitutions of a single
gene or multiple genes. Cystic fibrosis (CF), an autosomal recessive hereditary disease, is caused by mutations
of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. In healthy cells, CFTR maintains
chloride and bicarbonate transportation as an ion channel. Genetic defects of CFTR result in complicated
respiratory and systemic organ failure. Point mutations, or single-nucleotide variations (SNVs), account for ~60%
of the pathogenic variants causing CF. CF patients can be partially treated by the administration of small
molecule drugs to improve symptoms, including chronic pulmonary disease and pancreatic insufficiency.
However, CF mutations leading to the premature termination codon (PTC) affect at least 10% of CF patients,
whose symptoms cannot be relieved by any of the modulators. Gene therapy is a promising and permanent
alternative approach that confers therapeutic benefits to patients who suffer from genetic diseases. The CRISPR-
Cas9 system can efficiently cause double-strand breaks (DSBs) to facilitate homology-directed repair (HDR) for
accurate gene-editing outcomes. However, safety concerns arising from the DSBs cause unwanted mutations.
To surmount this problem, base editors (BEs) use a nickase Cas9 (nCas9) that nicks only the protospacer
adjacent motif (PAM)-containing strand, and thus eliminates the risk of DSBs and random indels. BEs use a
natural or engineered DNA deaminase fused with a nCas9 and can introduce a C-to-T or an A-to-G conversion
within the activity window by the cytosine or adenine deaminase. Both cytosine BEs (CBEs) and adenine BEs
(ABEs) can enable base transitions with high efficiency and have already proven successful for a few genetic
diseases in proof-of-concept studies. However, before applying BEs to the treatment of human genetic diseases,
including CF, several challenges must be overcome. First, indiscriminate conversion of multiple ‘C’s or ‘A’s within
CBE or ABE’s characteristic deamination activity window, usually more than five nucleotides, results in undesired
bystander editing. Second, the targeting scope of BEs has been largely constrained by the NGG PAM
requirement of nSpCas9, the canonical Cas9 from Streptococcus pyogenes. A large proportion of the base
transition pathogenic mutations is thus unavailable for editing. Third, the lack of multiplexity of BEs impedes its
practicality in processing multiple mutations simultaneously for the treatment of complex genetic diseases. In
this proposed research, we aim to develop precise and multiplex BEs that will make it possible to target the vast
majority of human genome sites (Aim 1 & 2). We will apply high-precision BEs to generate and correct
homozygous and compound heterozygous CF disease models that mirror individual patients, which will also
greatly facilitate pharmacological research and drug discovery for personalized CF treatment (Aim 3). In
summary, high-precision BEs will contribute to personalized gene therapy for cystic fibrosis as well as many
other genetic diseases.
项目摘要/摘要
遗传性疾病和遗传性疾病是由单个基因的插入、缺失和碱基替换引起的
基因或多个基因。囊性纤维化是一种常染色体隐性遗传性疾病,由突变引起
囊性纤维化跨膜传导调节因子(CFTR)基因。在健康细胞中,CFTR坚持认为
氯化物和碳酸氢盐作为离子通道运输。CFTR的遗传缺陷导致复杂
呼吸系统和全身器官衰竭。点突变或单核苷酸变异(SNV)约占60%
引起CF的致病变异体。Cf患者可以通过使用小剂量的
改善症状的分子药物,包括慢性肺部疾病和胰腺功能不全。
然而,导致过早终止密码子(PTC)的CF突变至少影响10%的CF患者,
其症状不能被任何调节剂缓解。基因治疗是一种有希望的、永久的
为患有遗传病的患者提供治疗益处的另一种方法。CRISPR-
Cas9系统可有效地导致双链断裂(DSB)以促进同源定向修复(HDR)
准确的基因编辑结果。然而,DSB引起的安全问题会导致不必要的突变。
为了克服这个问题,基本编辑(BE)使用了一个昵称Cas9(NCas9),它只删除Protspacer
含有邻近基序(PAM)的链,从而消除了DSB和随机INDELs的风险。BES使用
天然或工程DNA脱氨酶与nCas9融合,可实现C-T或A-G转换
活性窗口内的胞嘧啶或腺嘌呤脱氨酶。胞嘧啶BES(CBEs)和腺嘌呤BES
(ABES)可以高效地实现碱基转换,并已被证明对一些基因成功
概念验证研究中的疾病。然而,在将BES应用于治疗人类遗传病之前,
包括合作伙伴关系在内,必须克服几个挑战。首先,不分青红皂白地转换内部的多个C或A
CBE或ABE特有的脱氨活性窗口,通常超过5个核苷酸,导致不受欢迎的结果
旁观者编辑。其次,BES的目标范围在很大程度上受到了NGG PAM的限制
化脓性链球菌对典型Cas9基因nSpCas9的要求基地的很大比例
因此,无法编辑过渡致病突变。第三,缺乏BES的多元性阻碍了其
同时处理多个突变以治疗复杂遗传病的实用性。在……里面
这项拟议的研究,我们的目标是开发精确的和多路BES,使其有可能针对广大
大多数人类基因组位置(目标1和2)。我们将应用高精度的BES来生成和校正
反映单个患者的纯合子和复合杂合性CF疾病模型,这也将
极大地促进个性化治疗的药理研究和药物发现(目标3)。在……里面
总结:高精度的BES将有助于囊性纤维化的个性化基因治疗,以及许多
其他遗传性疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xue Gao其他文献
Xue Gao的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xue Gao', 18)}}的其他基金
Develop High-Precision and Multiplex Base Editing Approaches for Therapeutic Applications
开发用于治疗应用的高精度和多重碱基编辑方法
- 批准号:
10185829 - 财政年份:2021
- 资助金额:
$ 52.54万 - 项目类别:
Develop High-Precision and Multiplex Base Editing Approaches for Therapeutic Applications
开发用于治疗应用的高精度和多重碱基编辑方法
- 批准号:
10383725 - 财政年份:2021
- 资助金额:
$ 52.54万 - 项目类别:
Advancing CRISPR-Cas Technologies for the Discovery and Characterization of Novel Fungal Natural Products
推进 CRISPR-Cas 技术用于新型真菌天然产物的发现和表征
- 批准号:
10029379 - 财政年份:2020
- 资助金额:
$ 52.54万 - 项目类别:
Supplement to Advancing CRISPR-Cas Technologies for the Discovery and Characterization of Novel Fungal Natural Products
先进 CRISPR-Cas 技术的补充,用于新型真菌天然产物的发现和表征
- 批准号:
10805704 - 财政年份:2020
- 资助金额:
$ 52.54万 - 项目类别:
Advancing CRISPR-Cas Technologies for the Discovery and Characterization of Novel Fungal Natural Products
推进 CRISPR-Cas 技术用于新型真菌天然产物的发现和表征
- 批准号:
10624347 - 财政年份:2020
- 资助金额:
$ 52.54万 - 项目类别:
Advancing CRISPR-Cas Technologies for the Discovery and Characterization of Novel Fungal Natural Products
推进 CRISPR-Cas 技术用于新型真菌天然产物的发现和表征
- 批准号:
10223384 - 财政年份:2020
- 资助金额:
$ 52.54万 - 项目类别:
Undergraduate Jeffrey Vanegas Research Experience for underrepresented biomedical research students
本科杰弗里·瓦内加斯(Jeffrey Vanegas)为代表性不足的生物医学研究生提供的研究经验
- 批准号:
10408899 - 财政年份:2020
- 资助金额:
$ 52.54万 - 项目类别:
Supplement to Advancing CRISPR-Cas Technologies for Discovery and Characterization of Novel Fungal Natural Products
先进 CRISPR-Cas 技术的补充,用于新型真菌天然产物的发现和表征
- 批准号:
10393788 - 财政年份:2020
- 资助金额:
$ 52.54万 - 项目类别:
Advancing CRISPR-Cas Technologies for the Discovery and Characterization of Novel Fungal Natural Products
推进 CRISPR-Cas 技术用于新型真菌天然产物的发现和表征
- 批准号:
10397411 - 财政年份:2020
- 资助金额:
$ 52.54万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 52.54万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 52.54万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 52.54万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 52.54万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 52.54万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 52.54万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 52.54万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 52.54万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 52.54万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 52.54万 - 项目类别:
Grant-in-Aid for Early-Career Scientists